Jon Napitupulu

AnaptysBio will separate its business into two public companies in the second quarter of 2026, potentially as early as...

Dyadic Applied Biosolutions and Denmark’s Inzymes plan to commercialize a recombinant, non-animal bovine chymosin for cheese production in 2026,...

uniQure reported full-year 2025 results and a pivotal regulatory update: after a Type A meeting in January, FDA advised...

Zymeworks has set a clear 2026 inflection point: its partner plans to submit a supplemental BLA for Ziihera (zanidatamab-hrii)...

Belite Bio reported positive topline results from its pivotal Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt...

Bavarian Nordic’s board has begun a CEO succession process as Paul Chaplin prepares to step down for personal reasons,...

Denali Therapeutics has finalized U.S. launch readiness for tividenofusp alfa (DNL310) in Hunter syndrome ahead of an April 5,...

Pacira BioSciences posted 2025 revenue of $726 million, up 4% year over year, with a record fourth quarter for...

Biodesix reported a breakout quarter to close 2025, delivering $28.8 million in Q4 revenue with 83% gross margins and,...

mdxhealth posted fourth-quarter revenue of $29.5 million, up 19% year over year, and full-year 2025 revenue of $107.9 million,...